Analysis of CD160+CD8+ lymphocyte subsets of influenza A virus infectors

doi:10.3877/cma.j.issn.1674-1358.2020.03.005

Abstract

Abstract:

Objective

To investigate the characteristics of CD160⁺CD8⁺ T lymphocyte subsets in peripheral blood of patients with influenza A virus (IAV) infection.

Methods

Total of 37 patients with IAV infection and 51 healthy controls in the same period were recruitmented in Peking University Ditan Teaching Hospital from December 2018 to March 2019, and the frequencies of CD160⁺CD8⁺ T cells in peripheral blood of different differentiation stages were detected by multicolor flow cytometry.

Result

Compared with health controls, the frequencies of CD160⁺CD8⁺ T cells in peripheral blood of patients with IAV infection decreased [24.50% (14.70%, 44.10%) vs. 8.85% (5.14%, 18.15%)], with significant difference (U = 326.00, P < 0.001). Compared with the controls, these decrease occurred in the four subsets of CD8⁺ T cells that include the naive T cells (T_N) [3.88% (1.28%, 9.48%) vs. 0.22% (0.12%, 0.60%)], central memory T cells (T_CM) [8.70% (4.43%, 15.80%) vs. 1.51% (0.69%, 2.54%)], effector memory T cells (T_EM) [22.30% (13.80%, 30.40%) vs. 7.71% (5.23%, 16.25%)] and effective memory re-expressing T cells (T_EMRA) [(46.99 ± 22.91) % vs. (21.60 ± 13.38) %] of cases with IAV infection, with significant differences (U = 238.50, 81.50, 412.00, t = 6.03; all P < 0.001). The proportion of CD160⁺CD8⁺ T cells in the discharged patients with IAV infection was higher than that of admission [(8.92 ± 7.84) % vs. (16.40 ± 9.43) %], with significant difference (t = 4.09, P = 0.001), but still lower than that of health controls [24.50% (14.70%, 44.10%) vs (16.40 ± 9.43) %], with significant difference (U = 209.50, P = 0.0029).

Conclusions

The frequency of CD160⁺CD8⁺ T cell subsets in peripheral blood T lymphocytes of patients with IAV infection decreased significantly, and may be an important manifestation of immune imbalance.

Key words: CD160 inhibitory, Multi-color flow, Severe influenza A, T cells

Xiaoxue Xu, Beibei Wang, Rui Song, Yangzi Song, Xue Zhao, Yu Jiang, Yu Cao, Hui Zeng. Analysis of CD160⁺CD8⁺ lymphocyte subsets of influenza A virus infectors[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(03): 206-211.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2020.03.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2020/V14/I03/206

Figures/Tables 7

References 25

[1]	Wendel I, Matrosovich M, Klenk HD. Snapshot: evolution of human influenza A viruses[J]. Cell Host Microbe,2015,17(3):416-416. e1.
[2]	Hamada H, Bassity E, Flies A, et al. Multiple redundant effector mechanisms of CD8⁺ T cells protect against influenza infection[J]. J Immunol,2013,190(1):296-306.
[3]	Sun J, Braciale TJ. Role of T cell immunity in recovery from influenza virus infection[J]. Curr Opin Virol,2013,3(4):425-429.
[4]	Attanasio J, Wherry EJ. Costimulatory and coinhibitory receptor pathways in infectious disease[J]. Immunity,2016,44(5):1052-1068.
[5]	Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection[J]. Nat Immunol,2008,10(1):29-37.
[6]	Rutishauser RL, Hartogensis W, Deguit CD, et al. Early and delayed antiretroviral therapy results in comparable reductions in CD8⁺ T cell exhaustion marker expression[J]. AIDS Res Hum Retroviruses, 2017,33(7):658-667.
[7]	Maïza H, Leca G, Mansur IG, et al. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity[J]. J Exp Med,1993,178(3):1121-1126.
[8]	Peretz Y, He Z, Shi Y, et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction[J]. PLoS Pathog,2012,8(8):1-13.
[9]	中华人民共和国中央人民政府. 流行性感冒诊疗方案(2018年版修订版)[EB/OL]. 2018-11-19. URL
[10]	Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8⁺ T cells[J]. J Exp Med1,997,186(9):1407-1418.
[11]	Erickson JJ, Rogers MC, Tollefson SJ, et al. Multiple inhibitory pathways contribute to lung CD8⁺ T cell impairment and protect against immunopathology during acute viral respiratory infection[J]. J Immunol,2016,197(1):233-243.
[12]	Alwis R D, Bangs D J, Angelo M A, et al. Immunodominant dengue virus-specific CD8⁺ T cell responses are associated with a memory PD-1⁺ phenotype[J]. J Virol,2016,90(9):4771-4779.
[13]	Chatterjee B, Deng Y, Holler A, et al. CD8⁺ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo[J]. PLoS Pathog,2019,15(5):1-27.
[14]	Maeda M, Carpenito C, Russell R C, et al. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class Ⅰ and regulates NK cell activation[J]. J Immunol,2005,175(7):4426-4432.
[15]	Cai G, Anumanthan A, Brown J A, et al. CD160 inhibits activation of human CD4⁺ T cells through interaction with herpesvirus entry mediator[J]. Nat Immunol,2008,9(2):176-185.
[16]	D’Addio F, Ueno T, Clarkson M, et al. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival[J]. PLoS One,2013,8(4):1-11.
[17]	Tan CL, Peluso MJ, Drijvers JM, et al. CD160 stimulates CD8⁺ T cell responses and is required for optimal protective immunity to Listeria monocytogenes[J]. Immunohorizons,2018,2(7):238-250.
[18]	Chibueze CE, Yoshimitsu M, Arima N. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection[J]. Biochem Biophys Res Commun,2014,453(3):379-384.
[19]	Cooksley H, Riva A, Katzarov K, et al. Differential expression of immune inhibitory checkpoint signatures on antiviral and inflammatory T cell populations in chronic hepatitis B[J]. J Interferon Cytokine Res,2018,38(7):273-282.
[20]	Pombo C, Wherry E J, Gostick E, et al. Elevated expression of CD160 and 2B4 defines a cytolytic HIV-specific CD8⁺ T-cell population in elite controllers[J]. J Infect Dis,2015,212(9):1376-1386.
[21]	El-Far M, Pellerin C, Pilote L, et al. CD160 isoforms and regulation of CD4 and CD8 T-cell responses[J]. J Transl Med,2014,12(1):1-29.
[22]	Baitsch L, Legat A, Barba L, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization[J]. PLoS One,2012,7(2):1-10.
[23]	Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol,2013,13(4):227-242.
[24]	Yamamoto T, Price D A, Casazza J P, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8⁺ T-cell exhaustion in HIV infection[J]. Blood,2011,117(18):4805-4815.
[25]	Bengsch B, Seigel B, Ruhl M, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8⁺ T cells is linked to antigen recognition and T cell differentiation[J]. PLoS Pathog,2010,6(6):1-14.

指标		健康对照	IAV感染者	统计量	P值
年龄（ ± s，岁）		62 ± 12	66 ± 13	t = 1.56	0.122
性别（例，男/女）^a		22/29	20/17	χ² = 1.02	0.312
血细胞		?	?	?	?
?	白细胞总数（ ± s，× 10⁹/L）	6.07 ± 1.38	7.38 ± 3.29	t = 2.56	0.012
?	中性粒细胞[M（P25，P75），× 10⁹/L]	3.19（2.73，4.02）	5.38（4.03，7.47）	U = 456.00	< 0.001
?	淋巴细胞[M（P25，P75），× 10⁹/L]	2.04（1.58，2.37）	0.98（0.58，1.19）	U = 188.50	< 0.001
?	红细胞（ ± s，× 10⁹/L）	4.62 ± 0.47	4.68 ± 0.61	t = 4.68	< 0.001
?	血小板（ ± s，× 10⁹/L）	234.50 ± 55.52	136.70 ± 84.50	t = 6.55	< 0.001
肝肾功能指标		?	?	?	?
?	肌酐[M（P25，P75），μmol/L]	69.00（57.00，78.75）	68.50（56.55，85.70）	U = 807.00	0.547
?	丙氨酸氨基转移酶[M（P25，P75），U/L]	15.80（12.55，23.25）	17.70（14.05，26.85）	U = 785.50	0.256
?	天冬氨酸氨基转移酶[M（P25，P75），U/L]	19.90（16.80，24.30）	29.75（22.95，42.30）	U = 404.00	< 0.001
?	总胆红素（ ± s，U/L）	11.70 ± 3.59	9.58 ± 4.38	t = 2.48	0.015
?	直接胆红素[M（P25，P75），U/L]	3.80（3.25，4.60）	3.90（2.78，5.93）	U = 814.50	0.375
?	白蛋白[M（P25，P75），g/L]	47.30（45.75，48.80）	34.50（31.85，37.68）	U = 42.00	< 0.001

指标		健康对照	IAV感染者	统计量	P值
年龄（ ± s，岁）		62 ± 12	66 ± 13	t = 1.56	0.122
性别（例，男/女）^a		22/29	20/17	χ² = 1.02	0.312
血细胞		?	?	?	?
?	白细胞总数（ ± s，× 10⁹/L）	6.07 ± 1.38	7.38 ± 3.29	t = 2.56	0.012
?	中性粒细胞[M（P25，P75），× 10⁹/L]	3.19（2.73，4.02）	5.38（4.03，7.47）	U = 456.00	< 0.001
?	淋巴细胞[M（P25，P75），× 10⁹/L]	2.04（1.58，2.37）	0.98（0.58，1.19）	U = 188.50	< 0.001
?	红细胞（ ± s，× 10⁹/L）	4.62 ± 0.47	4.68 ± 0.61	t = 4.68	< 0.001
?	血小板（ ± s，× 10⁹/L）	234.50 ± 55.52	136.70 ± 84.50	t = 6.55	< 0.001
肝肾功能指标		?	?	?	?
?	肌酐[M（P25，P75），μmol/L]	69.00（57.00，78.75）	68.50（56.55，85.70）	U = 807.00	0.547
?	丙氨酸氨基转移酶[M（P25，P75），U/L]	15.80（12.55，23.25）	17.70（14.05，26.85）	U = 785.50	0.256
?	天冬氨酸氨基转移酶[M（P25，P75），U/L]	19.90（16.80，24.30）	29.75（22.95，42.30）	U = 404.00	< 0.001
?	总胆红素（ ± s，U/L）	11.70 ± 3.59	9.58 ± 4.38	t = 2.48	0.015
?	直接胆红素[M（P25，P75），U/L]	3.80（3.25，4.60）	3.90（2.78，5.93）	U = 814.50	0.375
?	白蛋白[M（P25，P75），g/L]	47.30（45.75，48.80）	34.50（31.85，37.68）	U = 42.00	< 0.001

组别	例数	CD8⁺ T细胞亚群
组别	例数	T_N [M（P25，P75），%]	T_CM（ ± s，%）	T_EM（ ± s，%）	T_EMRA [M（P25，P75），%]
健康对照	51	13.60（5.17，31.40）	5.54 ± 4.28	38.78 ± 14.00	34.80（22.80，48.80）
IAV感染者	37	12.60（3.60，26.95）	6.97 ± 6.69	52.38 ± 22.24	18.60（8.86，32.40）
统计量	?	U = 852.00	t = 1.22	t = 3.51	U = 496.50
P值	?	0.4425	0.2244	< 0.001	< 0.001

组别	例数	CD8⁺ T细胞亚群
组别	例数	T_N [M（P25，P75），%]	T_CM（ ± s，%）	T_EM（ ± s，%）	T_EMRA [M（P25，P75），%]
健康对照	51	13.60（5.17，31.40）	5.54 ± 4.28	38.78 ± 14.00	34.80（22.80，48.80）
IAV感染者	37	12.60（3.60，26.95）	6.97 ± 6.69	52.38 ± 22.24	18.60（8.86，32.40）
统计量	?	U = 852.00	t = 1.22	t = 3.51	U = 496.50
P值	?	0.4425	0.2244	< 0.001	< 0.001

组别	例数	CD8⁺ T细胞亚群
组别	例数	T_N [M（P25，P75），%]	T_CM [M（P25，P75），%]	T_EM [M（P25，P75），%]	T_EMRA（ ± s，%）
健康对照	51	3.88（1.28，9.48）	8.70（4.43，15.80）	22.30（13.80，30.40）	46.99 ± 22.91
IAV感染者	37	0.22（0.12，0.60）	1.51（0.69，2.54）	7.71（5.23，16.25）	21.60 ± 13.38
统计量	?	U = 238.50	U = 81.50	U = 412.00	t = 6.03
P值	?	< 0.001	< 0.001	< 0.001	< 0.001

Please choose a citation manager

Content to export